Brief: Newron Pharmaceuticals To Prioritize Its Phase III Development Program Of Evenamide In Schizophrenia
04/05/2020 06:06
May 4 (Reuters) - NEWRON PHARMACEUTICALS SPA NWRN.S :
* REPORTS TOP-LINE RESULTS FROM ITS STARS STUDY EVALUATING
SARIZOTAN IN PATIENTS WITH RETT SYNDROME
* PIVOTAL TRIAL DID NOT MEET PRIMARY OR SECONDARY EFFICACY
VARIABLES
* NEWRON WILL PRIORITIZE ITS PHASE III DEVELOPMENT PROGRAM
OF
EVENAMIDE IN SCHIZOPHRENIA AND EVALUATE ADDITIONAL PIPELINE
CANDIDATES
Source text for Eikon: ID:nEQYLTf9a
Further company coverage: NWRN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study